Human Anti-ENV Recombinant Antibody (clone 2F5) (CAT#: PABZ-141)

Figure 1 SHIV neutralization by 2F5, 4E10, and b12 in a rhesus PBMC assay and a pseudovirus luciferase reporter gene assay

Hessell, A. J., Rakasz, E. G., Tehrani, D. M., Huber, M., Weisgrau, K. L., Landucci, G., ... & Burton, D. R. (2010). Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. Journal of virology, 84(3), 1302-1313.

Figure 2 Protection by 2F5 and 4E10 against mucosal SHIV_Ba-L challenge.

A total of 16 male Indian rhesus macaques were divided into two antibody treatment groups of six for administration of 2F5 and 4E10. The control group was comprised of two isotype control-treated animals and two control animals (96068 and 2025) that were challenged prior to the beginning of the protection study to confirm viral infectivity but not treated with antibody. All animals were intrarectally challenged with 2,000 TCID₅₀ SHIV_Ba-L. Animals in the antibody treatment groups received an intravenous dose of 50 mg/kg of either 2F5, 4E10, or isotype control antibody 1 day prior to viral challenge (day - 1) and again 1 day following viral challenge (day + 1). All control animals (4/4) experienced peak viremia on the order of 107 between days 14 and 21. A single animal (2F5-treated 93060), experienced very low-level transient viremia, but at the end of 6 weeks there was no detectable virus in any of the animals. The presence of virus was measured in an assay with a minimum detection limit of 150 SIV RNA copies per ml (2.1 log₁₀ vRNA copies/ml) with a 95% confidence level. A second assay with a minimum detection limit of 10 SIV RNA copies per ml was used to retest available samples of sufficient volume (Table 2).

Hessell, A. J., Rakasz, E. G., Tehrani, D. M., Huber, M., Weisgrau, K. L., Landucci, G., ... & Burton, D. R. (2010). Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. Journal of virology, 84(3), 1302-1313.

Figure 3 Antibody-dependent cell-mediated viral inhibition (ADCVI) of 2F5 and 4E10 in comparison to b12.

Target cells (CEM.NKRCCR5) were infected with SHIVBa-L, incubated for 48 h, and then washed to remove cell-free virus. Serially diluted antibody was added at 50, 2, and 0.4 μg/ml to effector cells (rhesus PBMCs) and incubated for 30 min. Effectors and diluted antibody were combined with targets at an effector-to-target ratio of 10:1 and incubated for 7 days at 37°C in 5% CO2. Supernatant was collected and assayed for p27 by ELISA to measure viral inhibition.

Hessell, A. J., Rakasz, E. G., Tehrani, D. M., Huber, M., Weisgrau, K. L., Landucci, G., ... & Burton, D. R. (2010). Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. Journal of virology, 84(3), 1302-1313.